Multicenter Early Feasibility Trial Studying the Renata Minima Stent

Learn more about:
Related Clinical Trial

Brief Title

Multicenter Early Feasibility Trial Studying the Renata Minima Stent

Official Title

Multicenter Early Feasibility Trial of Neonatal, Infant, and Young Child Vascular Stenoses Studying the Renata Minima Stent

Brief Summary

      The objective of the clinical investigation is to access device performance and the initial
      clinical safety and effectiveness of the Minima Stent in neonates, infants, and young
      children requiring intervention for common congenital vascular stenosis (i.e., coarctation of
      the aorta and/or pulmonary artery stenosis) who are indicated for treatment.

Study Type


Primary Outcome


Secondary Outcome

 Arterial to arterial peak-to-peak pressure gradient to < 20 mmHg


Coarctation of the Aorta


Catheterized Stenting


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 2021

Completion Date

June 2027

Primary Completion Date

June 2022

Eligibility Criteria

        Inclusion Criteria:

          -  The subject's legally authorized representative has been informed of the nature of
             the- clinical investigation, agrees to its provisions, and has provided written
             informed consent

          -  Requiring treatment of:

               -  native or recurrent aortic coarctation, and/or

               -  native or recurrent pulmonary artery stenosis

               -  Vascular stenosis measuring < or equal to 50% of normal adjacent vessel

          -  Patency of at least one femoral vein, femoral artery, jugular vein or both carotid
             arteries able to accommodate the delivery system

          -  Adjacent vessel to stenosis measuring > or equal to 4 mm

        Exclusion Criteria:

          -  Active bloodstream infection requiring antibiotic therapy within 3 days prior to stent

          -  History of or active endocarditis (active treatment with antibiotics) within 180 days
             prior to stent implantation

          -  Aortic or pulmonary artery aneurysm in close proximity to the target lesion

          -  Body weight of < 1.5 kg

          -  Anatomic location of lesion judged by the investigator to not lend to the safe
             placement of a stent

          -  Target vessels larger or smaller than the Minima System balloon size ranges

          -  Currently participating in an investigational drug study or another device study

          -  Major or progressive non-cardiac disease resulting in a life expectancy of less than
             six months

          -  Known hypersensitivity to aspirin or heparin and cannot be treated with other
             antiplatelet and/or antithrombotic medications

          -  Known hypersensitivity to cobalt-chromium or contrast media that cannot be adequately




N/A - N/A

Accepts Healthy Volunteers



, 8015569954, [email protected]

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Renata Medical

Study Sponsor

, , 

Verification Date

October 2021